GOSSAMER BIO, INC. (GOSS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $50.00K; Additional Paid in Capital, Common StockUSD $1.38B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.73M; Retained Earnings (Accumulated Deficit)USD $-1.47B.
- 2026-03-31: Common Stock, Value, IssuedUSD $24.00K; Additional Paid in Capital, Common StockUSD $1.33B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.02M; Retained Earnings (Accumulated Deficit)USD $-1.49B.
- 2025-12-31: Common Stock, Value, IssuedUSD $24.00K; Additional Paid in Capital, Common StockUSD $1.32B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-5.15M; Retained Earnings (Accumulated Deficit)USD $-1.44B.
- 2025-09-30: Common Stock, Value, IssuedUSD $24.00K; Additional Paid in Capital, Common StockUSD $1.31B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-5.11M; Retained Earnings (Accumulated Deficit)USD $-1.39B.
GOSSAMER BIO, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Adjustments to Additional Paid in Capital, Other USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $50.00K | $1.38B | $-3.73M | $-1.47B | $-94.03M | (m) | 3 month · $2.46M | (m) | (m) |
| 2026-03-31 | $24.00K | $1.33B | $-4.02M | $-1.49B | $-161.48M | (m) | 3 month · $6.30M | (m) | (m) |
| 2025-12-31 | $24.00K | $1.32B | $-5.15M | $-1.44B | $-122.76M | (m) | 12 month · $10.55M | (m) | (m) |
| 2025-09-30 | $24.00K | $1.31B | $-5.11M | $-1.39B | $-82.33M | (m) | 3 month · $2.67M | (m) | (m) |
| 2025-06-30 | $23.00K | $1.30B | $-5.09M | $-1.34B | $-46.11M | (m) | 3 month · $2.59M | (m) | (m) |
| 2025-03-31 | $23.00K | $1.30B | $-824.00K | $-1.31B | $-6.25M | (m) | 3 month · $2.40M | (m) | (m) |
| 2024-12-31 | $23.00K | $1.30B | $1.19M | $-1.27B | $29.49M | (m) | 12 month · $20.62M | (m) | (m) |
| 2024-09-30 | $23.00K | $1.29B | $-2.23M | $-1.24B | $54.14M | (m) | 3 month · $4.84M | (m) | (m) |
| 2024-06-30 | $23.00K | $1.29B | $-518.00K | $-1.20B | $81.53M | (m) | 3 month · $5.00M | (m) | (m) |
| 2024-03-31 | $23.00K | $1.28B | $-628.00K | $-1.25B | $26.72M | (m) | 3 month · $5.81M | (m) | (m) |
| 2023-12-31 | $23.00K | $1.28B | $-350.00K | $-1.21B | $62.77M | 12 month · $10.78M | 12 month · $28.52M | (m) | (m) |
| 2023-09-30 | $23.00K | $1.27B | $-618.00K | $-1.16B | $104.62M | 3 month · $10.78M | 3 month · $6.16M | (m) | (m) |
| 2023-06-30 | $10.00K | $1.06B | $-481.00K | $-1.12B | $-62.80M | (m) | 3 month · $8.20M | (m) | (m) |
| 2023-03-31 | $10.00K | $1.05B | $-436.00K | $-1.08B | $-28.46M | (m) | 3 month · $8.13M | (m) | (m) |
| 2022-12-31 | $10.00K | $1.04B | $-574.00K | $-1.03B | $12.08M | 12 month · $184.00K | 12 month · $42.55M | (m) | (m) |
| 2022-09-30 | $10.00K | $1.03B | $-585.00K | $-976.46M | $56.35M | 3 month · $184.00K | 3 month · $10.12M | (m) | (m) |
| 2022-06-30 | $8.00K | $901.14M | $-514.00K | $-917.10M | $-16.46M | (m) | 3 month · $10.00M | (m) | (m) |
| 2022-03-31 | $8.00K | $891.12M | $-340.00K | $-860.63M | $30.16M | (m) | 3 month · $10.98M | (m) | (m) |
| 2021-12-31 | $8.00K | $932.94M | $45.00K | $-811.53M | $121.46M | (m) | 12 month · $32.01M | (m) | (m) |
| 2021-09-30 | $8.00K | $924.91M | $137.00K | $-755.25M | $169.81M | (m) | 3 month · $7.59M | $0.00 | (m) |
| 2021-06-30 | $8.00K | $915.41M | $274.00K | $-695.00M | $220.69M | (m) | 3 month · $8.05M | $0.00 | (m) |
| 2021-03-31 | $8.00K | $907.09M | $158.00K | $-635.17M | $272.08M | (m) | 3 month · $8.71M | $0.00 | (m) |
| 2020-12-31 | $8.00K | $897.61M | $599.00K | $-577.53M | $320.68M | 12 month · $109.00K | 12 month · $38.75M | $0.00 | 12 month · $16.00K |
| 2020-09-30 | $8.00K | $884.68M | $342.00K | $-512.93M | $372.10M | (m) | 3 month · $8.92M | (m) | 3 month · $16.00K |
| 2020-06-30 | $8.00K | $874.86M | $567.00K | $-455.11M | $420.32M | 3 month · $109.00K | 3 month · $8.90M | (m) | (m) |
| 2020-03-31 | $7.00K | $695.21M | $-505.00K | $-388.24M | $306.46M | (m) | 3 month · $8.24M | (m) | (m) |
| 2019-12-31 | $7.00K | $686.39M | $258.00K | $-334.17M | $352.49M | (m) | 12 month · $20.82M | (m) | (m) |
| 2019-09-30 | $7.00K | $678.01M | $328.00K | $-279.47M | $398.87M | (m) | 3 month · $5.73M | (m) | (m) |
| 2019-06-30 | $7.00K | $671.91M | $496.00K | $-230.97M | $441.44M | (m) | 3 month · $5.14M | (m) | 3 month · $39.00K |
| 2019-03-31 | $7.00K | $666.65M | $79.00K | $-186.47M | $480.26M | (m) | 3 month · $3.09M | (m) | (m) |
| 2018-12-31 | $2.00K | $33.85M | $-61.00K | $-153.86M | $-120.07M | (m) | 12 month · $30.95M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | $-91.78M | (m) | 3 month · $18.17M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | $-60.78M | (m) | 3 month · $1.37M | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | $-29.42M | (m) | 3 month · $605.00K | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | $-6.86M | (m) | 12 month · $32.00K | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | $-123.00K | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |